BeiGene Q3 EPADS $2.01 Beats $(3.09) Estimate, Sales $781.31M Beat $632.77M Estimate
Portfolio Pulse from Benzinga Newsdesk
BeiGene (NASDAQ:BGNE) reported Q3 earnings of $2.01 per share, beating the analyst consensus estimate of $(3.09) by 165.05%. This is a 137.29% increase over losses of $(5.39) per share from the same period last year. The company also reported quarterly sales of $781.31 million, beating the analyst consensus estimate of $632.77 million by 23.47%. This is a 101.56% increase over sales of $387.63 million the same period last year.
November 09, 2023 | 9:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BeiGene's Q3 earnings and sales significantly exceeded estimates, indicating strong financial performance. This could potentially lead to a positive impact on the company's stock price.
BeiGene's Q3 earnings and sales have significantly exceeded analyst estimates, indicating strong financial performance. This positive news is likely to be well received by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100